|
|
|
|
Office Locations:
|
160 5th Ave. #9
New York, NY 10010
| | |
|
|
|
|
|
Financial Services
Food & Agriculture
Life Sciences & Healthcare
|
|
|
|
Euclidean Capital is the family office for hedge fund billionaire James Simons. There is very little public information available on Euclidean. The firm is believed to be focused mostly on individual stocks, with a preference for biotech. Euclidean also invests in Life Sciences and Financial Services startups. Simons worked as a National Security Agency codebreaker, founded Stony Brook University's math department, won an Oswald Veblen Prize for his work as a geometrician and co-authored the Chern-Simons Theory, a building block for string theory. According to Forbes, Simons net worth exceeds $28 billion. The Simons Foundation supports basic and discovery-driven science, and the Simon's Flatiron Institute bankrolls computational research in astrophysics, biology, mathematics, neuroscience, and quantum physics.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Ashvin Chhabra | |
| |
President & Chief Investment Officer | |
| James Simons | |
| |
Founder | |
| Monique Miller | |
| |
Head of Investment Strategy | |
| Uche Abalogu | |
| |
CTO | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
10/30/2024
|
Leal Therapeutics
|
MA
|
$45,000,000
|
|
10/07/2024
|
Judo Bio
|
MA
|
$100,000,000
|
Seed and Series A
|
09/17/2024
|
Nura Bio
|
CA
|
$140,000,000
|
Series A
|
09/03/2024
|
Circle Pharma
|
CA
|
$90,000,000
|
Series D
|
06/24/2024
|
GrayMatter Robotics
|
CA
|
$45,000,000
|
Series B
|
06/13/2024
|
InduPro
|
WA
|
$85,000,000
|
Series A
|
03/25/2024
|
FundGuard
|
NY
|
$100,000,000
|
Series C
|
02/29/2024
|
Kenai Therapeutics
|
CA
|
$82,000,000
|
Series A
|
02/08/2024
|
Neurona Therapeutics
|
CA
|
$120,000,000
|
Venture
|
01/24/2024
|
Sion Power
|
AZ
|
$75,000,000
|
Series A
|
|
|
|
|
|
|
|
